I notice the question asks about "Kisunla," but the evidence provided exclusively addresses hypertension management guidelines. There is no information about Kisunla in any of the provided evidence sources.
Kisunla (donanemab-azbt) is an FDA-approved medication for Alzheimer's disease, not hypertension. The evidence database appears to contain only hypertension-related guidelines and research, which are not applicable to answering questions about Kisunla.
To provide accurate guidelines for Kisunla, I would need:
- FDA drug label information for donanemab-azbt
- Clinical practice guidelines for Alzheimer's disease treatment
- Relevant research on anti-amyloid monoclonal antibody therapy
- Safety monitoring protocols specific to this medication class
Without appropriate evidence sources about Kisunla/donanemab, I cannot provide treatment guidelines for this medication. The hypertension guidelines provided 1, 2, 3 and related research 4, 5, 6, 7, 8 address an entirely different therapeutic area and would be misleading if applied to Alzheimer's disease management.
If you intended to ask about hypertension management guidelines instead, please clarify and I can provide a comprehensive answer using the available evidence.